Lupin intros generic Tobi
Lupin has launched its generic Tobi (tobramycin inhalation solution). The drug is indicated to manage cystic fibrosis in patients with P. aeruginosa.
Lupin’s generic Tobi, which was previously approved by the Food and Drug Association, enters a market whose size was roughly $99 million for the 12 months ended April 2018, according to IQVIA data.
Lupin’s generic Tobi, which was previously approved by the Food and Drug Association, enters a market whose size was roughly $99 million for the 12 months ended April 2018, according to IQVIA data.